Monthly Prescribing Reference

Memantine Extended-release

Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl ...

Safe, low-cost Alzheimer's drug demonstrates efficacy against sickle cell anemia

Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...
Seeking Alpha

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil ...
Medscape

Rationale for Combining Glutamatergic and Cholinergic Approaches in the Symptomatic Treatment of Alzheimer's Disease

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have been ...
EurekAlert!

Alzheimer’s drug demonstrates efficacy against sickle cell anemia

Memantine, a long-approved and cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data from an international ...